pfizer - Search News

Novo Nordisk, Pfizer sweeten bid for Metsera

Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer

Pfizer Chairman and CEO Albert Bourla told analysts Tuesday morning that the Novo offer was “illusory” and cannot constitute a superior offer.

· 1h · on MSN

Novo Nordisk downgrades sales outlook again amid bidding war with Pfizer for Metsera

Fierce Biotech · 22h

Novo, Pfizer's bidding war heats up with supercharged offers for Metsera

Pfizer’s revenue falls

Digest more

· 21h · on MSN

Pfizer’s revenue falls as COVID sales and vaccine recommendations continue to fade

Shares of Pfizer Inc. gave up ground in early Tuesday trading, after the drug giant reported a decline in revenue, as strength in its blood-clot drug was offset by the continued drop-off in demand for...

· 21h · on MSN

Pfizer COVID-19 vaccine sales tumble after government guidance on the shots narrows

· 1d · on MSN

Pfizer tops estimates, raises profit guidance even as sales fall

RTE Online · 1d

Pfizer raises 2025 profit forecast for second time in a row

Pfizer has today lifted its full-year profit forecast for the second time in a row as robust demand for its blockbuster heart treatment and blood thinner helped it post third-quarter earnings above ex...

· 22h

Pfizer’s (NYSE:PFE) Q3 Earnings Results: Revenue In Line With Expectations

· 23h

Pfizer raises and narrows full-year earnings guidance

58mon MSN

Novo Nordisk CEO faces baptism of fire amid board shakeup, Pfizer fight

Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues a bidding war with U.S. rival Pfizer. The drugmaker will release third quarter results on Wednesday,

Fierce Biotech

Pfizer's parade of pipeline cuts: Seagen, BioNTech and MASH programs among 11 axed

Pfizer has axed 11 programs, including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage MASH combo.

18h

Pfizer’s Q3 Earnings Beat on Top and Bottom Lines

Pfizer (NYSE: PFE) beat earnings expectations decisively this morning, posting adjusted EPS of $0.87 against a $0.64 consensus and revenue of $16.65 billion versus $16.50 billion expected. The stock gapped up roughly 12.

The Business Times

Pfizer boosts profit view as it battles for obesity startup

[NEW YORK] Pfizer raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for slow sales growth that’s driving its battle for the obesity start up Metsera.